Blincyto Timeline And Reviewers

 
• By Bridget Silverman

Overview of development timeline and review team for Amgen’s Blincyto (blinatumomab) for relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL).

More from Archive

More from Pink Sheet